Statin Use Prior to Diagnosis Predicts High Risk Features in Early Stage Endometrioid Endometrial Cancer

Ruth D Stephenson; Lloyd H Smith

Statin Use Prior to Diagnosis Predicts High Risk Features in Early Stage Endometrioid Endometrial Cancer

Ruth D Stephenson^* and Lloyd H Smith: Department of Obstetrics and Gynecology, Davis MedicalCenter, University of California, Sacramento, California, USA

^*Corresponding Author : Ruth D Stephenson, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street Suite 2000, New Brunswick, NJ, 08903, USA, Tel: 585-313-5390, Email: RS1543@cinj.rutgers.edu

Received Date: Feb 08, 2018 / Accepted Date: Mar 12, 2018 / Published Date: Mar 26, 2018

Abstract

Objective: There is increasing evidence that statin use decreases the incidence and improves survival of gynecologic malignancies, but the role in endometrial cancer (EC) has not been defined. Our primary aim is to investigate statin use and its association with high intermediate risk (HIR) features in early stage EC. We hypothesize those women who develop early stage EC while taking statins have less aggressive features on pathology at the time of hysterectomy. Our secondary aim is to determine if concurrent use of other medications demonstrating anti-cancer effects; metformin, NSAIDs and bisphosphonates may reduce the risk of development of HIR early stage EC. Study
Design: Four-hundred patients with stage I EC who underwent hysterectomy at a single institution from 2008-2013 were reviewed to determine presence of any HIR features. lymph vascular space invasion, Grade 2 or 3 and greater than 50% my invasion. Associations between statin use and presence of any HIR features at the time of hysterectomy were examined using multivariate logistic regression adjusting for age, BMI, parity, diabetes, and hypertension. Baseline metformin, NSAIDs, and bisphosphonate use was also included in the analysis.
Results: Of the 400 patients, 75 (18.8%) had at least one high intermediate risk feature, and 124 (28.5%) were taking a statin at the time of diagnosis. Thirty one percent of our patients had BMI >30, 74% of our patients were younger than 70, 21% had a diagnosis of diabetes, 36% of hypertension. Statin use was associated with increased high risk features (OR 2.4, 95% CI 1.3-4.3) at the time of hysterectomy. There was a non-significant higher percentage of patients who recurred in the Statin users 10.5% (12/114) v 6.3% (18/286) in non-users. (p=0.15).
Conclusion: Our findings suggest that statin use confers a two times greater risk of having high risk features at the time of hysterectomy for early stage endometrial cancer. Statin use may prevent early stage low risk endometrial cancer, leading to an increased number of patients with HIR features in our statin user population.

Keywords: Endometrial cancer; Gynecologic cancer; Hypertension; Metabolic-syndrome

View PDF Download PDF

Citation: Stephenson RD, Smith LH (2018) Statin Use Prior to Diagnosis Predicts High Risk Features in Early Stage Endometrioid Endometrial Cancer. J Oncol Res Treat 3: 121.

Copyright: © 2018 Stephenson RD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

黑料网

Journal of Oncology Research and Treatment
黑料网